Vered Caplan, the CEO of Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, said her business is undergoing a “very exciting time” thanks to regulators working together to get cell therapies to patients, according to a Fox Business Network interview on the program “Mornings with Maria” held on Thursday.
“I think it’s very impressive how globally regulatory agencies have taken on the challenge of finding a way to get these drugs to patients,” Caplan said on the program.
"It’s exciting to see how scientists and regulatory people around the world are working together. Even a bone marrow transplantation is a cell therapy,” added Caplan.
READ: Orgenesis seals pact with Ben-Gurion University to develop dissolvable carriers for cell culturing
Developing cell therapies offers up challenges as it’s impossible to devise them as you would a plastic or a chemical material. “Making these drugs, making these products is the biggest engineering challenge so to speak,” Caplan said on Fox. “This is living material. These are the cells of our body.”
A developer and manufacturer of advanced cell therapies, Orgenesis is building a unique and fundamental base platform of know-how and expertise for a multitude of cell types and for the regenerative medicine industry. Based in Germantown, Maryland, the company conducts much of its research in Belgium and has also recently opened an operation in Korea.
Orgenesis shares held steady at $5.17 in Thursday’s morning trading session.